国产成人精品日本亚洲999,99久久久国产精品免费蜜臀 ,v一区无码内射国产,被调教的少妇雅芳1一19,国产成人a亚洲精v品无码

更新于 4月21日

戰(zhàn)略規(guī)劃經(jīng)理/高級經(jīng)理(J16831)

2-4萬·16薪
  • 上海徐匯區(qū)
  • 5-10年
  • 碩士
  • 全職
  • 招1人

職位描述

行研項目評估
崗位職責:
POSITION SUMMARY:
You will support targeted, effective and efficient strategic planning and management by sourcing, synthesizing, summarizing, and providing key business analytics that enable informed decision-making that affect the overall Henlius corporate strategy from the angle of portfolio. You will provide objective information and insights using data and analytical techniques that support cross-functional stakeholders, including product development, regulatory affairs, portfolio management, manufacturing, marketing, pricing & market access teams.
POSITION ACCOUNTABILITIES:
1、Conduct commercial assessment and insights for candidate molecule/ disease area/ indication to shape the portfolio
?Communicate with Portfolio Governess Committee business manager on roadmap update
?Synthesize information for insight generation
?Integrate market data to support forecast modeling
?Work closely with brand team and finance team on forecast modeling
?Track and update competitive intelligence on a regular basis
2、Provide strategic recommendations to senior leadership via detailed assessment on latest market trends
?Support refining market research methodology for internal business needs
3、Work with vendors to ensure high-quality deliverables
?Work closely with cross-functional teams on strategy generation, shaping and implementation
?Coordinate cross-functional strategic & business planning and review cycles
?Engage and manage senior key stakeholders to achieve alignment
4、Develop and manage corporate initiatives serving the company’s objectives
任職要求:
QUALIFICATIONS:
Education:
?Master’s degree or above, with major in medical or pharmacy is preferred. A postgraduate degree is preferred.
Work Experience:
?Rich strategy, portfolio or BD related experience in healthcare, preferably pharmaceuticals
?Post-BSc with working experience in a consulting firm or/and corporate strategy related functions
?Have knowledge about China pharmaceutical industry
Skills:
?Proven experience and skills in project management, financial modeling, project management, and presentation
?Strong data processing and desk research capability
?Good communication skills
?Good spoken and written English level
?Good PowerPoint and Excel skills

工作地點

徐匯區(qū)上海復宏漢霖生物技術股份有限公司

職位發(fā)布者

鄒女士/HR

昨日活躍
立即溝通
公司Logo上海復宏漢霖生物技術股份有限公司
復宏漢霖(2696.HK)是一家國際化的創(chuàng)新生物制藥公司,致力于為全球患者提供可負擔的高品質(zhì)生物藥,產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領域,已在中國上市5款產(chǎn)品,在國際上市1款產(chǎn)品,18項適應癥獲批,3個上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來,復宏漢霖已建成一體化生物制藥平臺,高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心,按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范(GMP)標準進行生產(chǎn)和質(zhì)量管控,不斷夯實一體化綜合生產(chǎn)平臺,其中,上海徐匯基地已獲得中國和歐盟GMP認證,松江基地(一)也已獲得中國GMP認證。復宏漢霖前瞻性布局了一個多元化、高質(zhì)量的產(chǎn)品管線,涵蓋20多種創(chuàng)新單克隆抗體,并全面推進基于自有抗PD-1單抗H藥漢斯狀?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個生物類似藥漢利康?(利妥昔單抗)、中國首個自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?(曲妥珠單抗,歐洲商品名:Zercepac?,澳大利亞商品名:Tuzucip?和Trastucip?)、漢達遠?(阿達木單抗)和漢貝泰?(貝伐珠單抗)相繼獲批上市,創(chuàng)新產(chǎn)品漢斯狀?(斯魯利單抗)已獲批用于治療微衛(wèi)星高度不穩(wěn)定(MSI-H)實體瘤、鱗狀非小細胞肺癌和廣泛期小細胞肺癌,成為全球首個獲批一線治療小細胞肺癌的抗PD-1單抗,其食管鱗狀細胞癌適應癥的上市注冊申請也正在審評中。公司亦同步就16個產(chǎn)品在全球范圍內(nèi)開展30多項臨床試驗。
公司主頁